指南与共识泌尿生殖MR

IsoPSA®减少总前列腺特异性抗原≥4 ng/ml男性的活检和磁共振成像提供者推荐:一项真实世界观察性临床效用研究

IsoPSA® Reduces Provider Recommendations for Biopsy and Magnetic Resonance Imaging in Men with Total Prostate Specific Antigen ≥4 ng/ml: A Real-World Observational Clinical Utility Study.
指南 / 共识 · Urol Pract · 2021-12-20

在克利夫兰诊所健康系统38名提供者纳入900名评估前列腺癌的男性中,734名符合标准并接受IsoPSA检测。IsoPSA使前列腺活检推荐净减少55%(284 vs 638),磁共振成像推荐减少9%,IsoPSA结果与活检推荐高度一致(指数高于阈值者87%被推荐活检,低于阈值者92%未被推荐活检)。

要点

  • IsoPSA使总PSA≥4 ng/ml男性的前列腺活检推荐净减少55%(284 vs 638)。
  • IsoPSA使磁共振成像推荐减少9%。
  • IsoPSA指数高于阈值者87%被推荐活检,低于阈值者92%未被推荐活检。

核心结论

  • 在真实世界临床环境中,不同培训背景和实践环境的提供者迅速采纳IsoPSA,使PSA升高(≥4 ng/ml)患者的前列腺活检推荐率大幅降低,且活检推荐与IsoPSA结果高度一致。

研究设计与样本

  • 真实世界观察性临床效用研究,38名提供者(包括高级实践提供者、专科培训肿瘤科医生和普通泌尿科医生)来自克利夫兰诊所健康系统社区和学术地点,纳入900名评估前列腺癌的男性,734名符合纳入标准(年龄≥50岁、总血清PSA≥4且<100 ng/ml、无前列腺癌病史)并具有IsoPSA使用指征,使用标准模板记录IsoPSA结果前后的活检推荐。

诊断标准与关键数值

  • IsoPSA指数高于阈值者87%被推荐前列腺活检,低于阈值者92%未被推荐前列腺活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: We assessed the impact of the IsoPSA® test for prostate cancer risk assessment on provider patient management decisions in a real-world clinical setting.

METHODS: A total of 38 providers, including advanced practice providers, fellowship trained oncologists and general urologists in the Cleveland Clinic health system including both community-based practices and academic locations, enrolled 900 men being evaluated for prostate cancer; 734 met inclusion criteria (age ≥50 years, total serum prostate specific antigen [PSA] ≥4 and <100 ng/ml and no history of prostate cancer) and IsoPSA indication for use. A standard template was used to document biopsy recommendation prior to and after receiving IsoPSA results. The primary outcome was the number of biopsy and magnetic resonance imaging recommendation changes occurring after IsoPSA testing.

RESULTS: IsoPSA testing resulted in a 55% (284 vs 638) net reduction in recommendations for prostate biopsy for men with total PSA ≥4 ng/ml. Additionally, a 9% reduction in recommendations for magnetic resonance imaging was observed. There was strong concordance between IsoPSA results and provider recommendations for prostate biopsy, with 87% of patients with an IsoPSA index above the threshold recommended for biopsy and 92% of patients with an IsoPSA index below the threshold not recommended for biopsy.

CONCLUSIONS: In a real-world clinical setting, providers from diverse training backgrounds and practice settings readily adopted IsoPSA with substantial reductions in the rate of recommended prostate biopsies in patients with elevated PSA values (≥4 ng/ml). There was a high concordance between recommendation for or against prostate biopsy and the IsoPSA result.

来源:Urol Pract,查看原文。版权归原作者所有。

引用

  1. Scovell, Hettel, Abouassaly, et al. IsoPSA® Reduces Provider Recommendations for Biopsy and Magnetic Resonance Imaging in Men with Total Prostate Specific Antigen ≥4 ng/ml: A Real-World Observational Clinical Utility Study. Urol Pract. 2021. PMID: 37145695. doi:10.1097/UPJ.0000000000000291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。